1999
DOI: 10.1038/sj.gt.3300862
|View full text |Cite
|
Sign up to set email alerts
|

Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients

Abstract: Dendritic cells (DC) are highly specialized antigennon-transduced DC. Whereas transduction of marker presenting cells (APC) that initiate and modulate immune genes (LacZ or enhanced green fluorescence protein responses. They are essential for naive T cell activation, (EGFP) ) did not alter their potent allostimulatory activity, but may also play roles both in central and peripheral toler-DC transduced with CTLA4Ig exhibited striking reductions ance. Blockade of costimulatory pathways that provide the in cell s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
65
0

Year Published

1999
1999
2007
2007

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 98 publications
(66 citation statements)
references
References 51 publications
(58 reference statements)
1
65
0
Order By: Relevance
“…Murine DC have been genetically modified by others using retroviral gene therapy vectors (vIL-10) and adenoviral vectors (TGF-␤ and CTLA4Ig) and have been shown to be an effective strategy both in vitro and in vivo for induction of alloantigen-specific anergy. [30][31][32] Recently, DC have also been modified with Fas ligand and proven capable of prolonging allograft survival in a cardiac transplantation model. 33 It is clear from other studies that the form of IL-10 is important to its biological effect.…”
Section: Discussionmentioning
confidence: 99%
“…Murine DC have been genetically modified by others using retroviral gene therapy vectors (vIL-10) and adenoviral vectors (TGF-␤ and CTLA4Ig) and have been shown to be an effective strategy both in vitro and in vivo for induction of alloantigen-specific anergy. [30][31][32] Recently, DC have also been modified with Fas ligand and proven capable of prolonging allograft survival in a cardiac transplantation model. 33 It is clear from other studies that the form of IL-10 is important to its biological effect.…”
Section: Discussionmentioning
confidence: 99%
“…24 delivery of CTLA4Ig to DC also confers tolerogenic properties on these cells in vitro. 37 Gene therapy of graft rejection or autoimmune disease is at an early stage of development, and a variety of gene transfer technologies are under investigation. [46][47][48] The use of adenoviral vectors has already been well-documented, and with respect to transduction efficiency, it appears a most effective method to deliver foreign cDNA into DC.…”
Section: Discussionmentioning
confidence: 99%
“…32 Migration of such genetically engineered DC, adminis-tered either locally or systemically, to interact with Agspecific T cells, may promote tolerance induction, with minimization of the undesired systemic effects of the transgene product. Transduction of DC to express a variety of immunomodulatory transgene products, that either augment 33,34 or impair T cell responses, [35][36][37] has recently been demonstrated. Adenoviral gene delivery achieves high transduction efficiency in non replicating cells, but may be associated with the induction of antiviral immune responses, that limit the efficacy of subsequent doses of the transduced DC.…”
Section: Introductionmentioning
confidence: 99%
“…51,52 Combinations of these approaches, including gene-engineered DC expressing a variety of immunosuppressive molecules, have shown promise in allograft survival. [53][54][55][56][57][58][59] and are awaiting rigorous testing in the context of islet allograft transplantation. Considering successes and failures, it is perhaps fair to conclude that while gene vectors and cells alone may not have yet supported permanent islet allograft survival, their utility cannot be yet dismissed as many important parameters have still to be evaluated, including combinative approaches.…”
Section: Type I Diabetes Mellitus: the Autoimmune Processmentioning
confidence: 99%